Fetalix’s Post

🚀 We are thrilled to announce that Readily Diagnostics has been awarded funding from the Bio-X Accelerate Program! This support will enable us to further develop and introduce our next-generation rapid diagnostic tests for respiratory diseases, significantly improving patient care with faster and more accurate diagnostics. 🌟 Our innovative padlock probe technology is set to revolutionize healthcare by providing timely and precise results directly at the point of care. Stay tuned for more updates as we work towards making a positive impact in the healthcare industry. BIO-X Accelerate is a program with the goal of accelerating the development of innovation in the health and/or life science industry. The program uses an industrial approach to support life science-related projects that could fulfill well-defined needs and create IMPACT in healthcare, industry and society. Selected companies receive funding for their projects as well as continued support and access to experts within the BIO-X network.     BIO-X Accelerate with the theme IMPACT is a project by STUNS with strategic partners UIC, Connect Uppsala, Create Business Incubator, Lead (Business Incubator), Inkubera and supporting partners Linköping University Innovation, Uppsala University and Örebro University Holding.     The project is financed by European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS.     STUNS is the foundation for collaboration between the universities in Uppsala, business and society. STUNS Life science is a strategic hub for collaboration between private and public actors to contribute to sustainable knowledge-based growth - in life science, health and neighboring disciplines.  #HealthcareInnovation #Diagnostics #BioXAccelerate #LifeSciences #PatientCare #MedicalTechnology #ReadilyDiagnostics 

From Serendipity to Success: Our Journey as Co-founders Have you ever experienced those uncanny coincidences that hint at a grander design? Snahlata Singh and I, have had our fair share of these serendipitous moments throughout our careers. Back in 2020, we unknowingly published our research in the same volume of the Journal of Biosciences. We arrived at this serendipity just last week! But the coincidences didn’t stop there.. In 2017, I joined NCCS, the same year Snahlata left the institute. Although we missed each other by a whisker, our paths were destined to cross. We found ourselves in the same team at our previous organization, where we discovered our shared passion for precision medicine and biomarker research. Our collaboration was nothing short of magical. With each project, our synergy grew stronger, culminating in the decision to co-found BioMarkIQ. Today, we stand united in our mission to revolutionize diagnostic solutions and make a lasting impact on healthcare. These moments of serendipity have been more than just coincidences!! Those, who are interested in reading the serendipitous 45th volume of the Journal of Bioscience, read up here: Manasi: On Page 10: https://lnkd.in/diqDeHG9 Snahlata: On Page 97: https://lnkd.in/dv76fqwW #BioMarkIQ #CoFounders #PrecisionMedicine #Biomarkers #HealthcareInnovation #Serendipity

Last week, we achieved another important milestone for #TEHA's Life Sciences Community.    It was a pleasure to organize and moderate the roundtable discussion "Elevating Innovation in Life Sciences: Europe’s leading TTOs in the spotlight”, held at the wonderful facilities of Humanitas Research in Milan. This event marked a significant step in our journey though innovation in #LifeSciences, showcasing the pivotal role of technology transfer processes to bring innovation from bench to bedside. Many thanks to our speakers (Robert AL, MBA RTTP, Nunzio Gennaro Cifariello, E-MBA, Irene Fialka, Anji Miller Ph.D CLP RTTP, Paola Vella, Corrado Panzeri) and to the many leaders of research and innovation that participated in the discussion (Francesca Pasinelli, Fabio Terragni, Fabrizio Conicella, Vittoria Pavoncello, Emiliano Schena and many others).     Some of the key takeaways from the discussion:  - what pharma and biotech companies are really looking for is not just science, but rather a solution to a specific need. To be patient-centered, technology transfer offices (TTOs) should focus on finding solutions that can meet market demands and patients’ need. - Multidisciplinary strategies and diverse expertise are essential. Italian universities and TTOs should actively seek to educate and hire individuals with mixed scientific backgrounds, embracing multidisciplinary knowledge that spans various therapeutic areas.  - Despite progress such as the abolishment of the professors’ privilege, there are still many bureaucratic obstacles that continue to hinder the Italian competitiveness in the global arena of innovation. It is imperative to address these constraints, particularly at the public level, to accelerate the speed at which innovations enter the market.     We are very pleased to have created this opportunity for dialogue and to have highlighted the example of Humanitas as an Italian excellence in research and innovation.   #InnoTech #innovation #TechnologyTransfer 

News from across Campus - Artios and bit.bio were two of the few healthtechs to make the Sifted 100: UK & Ireland ranking of the top 100 fastest-growing start-ups by revenue growth. More: https://ow.ly/H1Tk50RbmLz - Axol Bioscience Ltd.'s collaboration agreement with StrataStem involves a large-scale library of human iPSCs derived from patients with Alzheimer’s Disease. Find out more about the concept of a 'clinical trial in a dish' model along with latest insights from a recent study: https://ow.ly/Czua50Rbm6c - the inaugural UK Proteostasis conference is taking place at The Babraham Institute on 8-9 May and promises to be a must-attend for those working in proteostasis research. Details: https://ow.ly/jMGF50R7rtA - To mark #EarthDay on Monday (April 22) our Estates & Waste team will hold a drop-in session in the Market Restaurant to share details on how we can work together to improve sustainability. Stop by between 11.30am and 1.30pm to find out about the segregation of plastics, our new sustainable bins and more!

Why locate at ONE BioHub and in the north east Scotland? 🏠👩🔬👨🔬 Life Sciences professionals share what ONE BioHub means to them and the reasons why they base themselves in the north east: David Blackbourn, stated: “I was drawn here by the fantastic life sciences cluster in the north-east of Scotland. It provides a gravitational pull for life scientists." Andy Porter, commented: “Many Aberdeen companies have their drugs in late-stage clinical development. About 70% of late-stage drug assets across Scotland are based in Aberdeen. That’s one of the things that really distinguishes the cluster in the city." Mirela Delibegovic, PhD, FRSE, said: “We’ve had a concept of the triple helix here in the north-east of Scotland for a while. That means a combination of academia, healthcare and industry. Now, ONE BioHub enables us all to work together.” Professor Blackbourn concurs: “ONE BioHub is the foundation to foster the development of start-up life sciences companies, helping to create a pipeline of new medicines, diagnostics and technologies that improve patient health, wellbeing and quality of life. It will catalyse and accelerate ambition by providing a go-to place, almost a one-stop shop for all that academics need to take their research forward.” Swipe through to find out more or read the full blog here: https://lnkd.in/gwbbgrS8 #ONEBioHub #LifeSciences

🔥 Exciting times and even more exciting projects ahead! 🔥 I did promise you all an update on what I am about for in the next chapter of mine! ✅ Grateful to have locked in some incredible consultancy work with inspiring teams. (Shout out to Ditte Marie Fog Ibsen & Alireza Kouchaki at oasicare). Supporting them, as they innovate, keeps me sharp and constantly learning. 🎓 💡 - I will highlight some of the interesting journeys along the way - stay tuned! ✅ At Medflow, things are moving fast. Our compliance software—think eQMS + project guidance is in Beta (eDMS + project guidance), and my co-founder is now full-time on the journey! (Shout out to Vlad Manea) With our current testing, we’re gearing up for a game-changing solution. In one year, uploading Word, Excel, and PDF files will be a thing of the past. 📈 🚀 ✅ I’m also thrilled to support nervapax, a startup bringing life back to cluster headache patients. This mission couldn’t be more important. 🧠 ✨ Currently in Stockholm for the next 3 days with Meike Sieburg while Fridel Laursen will take the stage and pitch in Malmö. 🎤 ⭐ And on top of it all, I’m teaching DTU - Technical University of Denmark’s master’s students in biomedical product development—preparing the next generation to make an impact is very dear to my heart. 🚀 🎓 and I will be reaching out to the big ones soon and invite them in to get closer to their future talents. Novo Nordisk Ambu A/S Coloplast Convatec Cook Medical Radiometer 3Shape and many more. #MedicalDevice #MedicalDevices #MDR #FDA #ClinicalDeveloment #ClinicalEvaluations #Regulatory #Innovation

Thank you Investival Showcase and Herke Van Hulst, Rabab Nasrallah, PhD, and Nadiya Ishnazarova for a wonderful panel speaking about Getting Drugs to Patients Faster - Investing in Discovery, Development & Clinical Trial Tech 🌟 Grateful and Inspired! 🌟 I had the incredible opportunity to participate in a dynamic panel discussion at the Investival Showcase alongside the brilliant Herke Van Hulst, Rabab Nasrallah, PhD, and Nadiya Ishnazarova. Our conversation focused on a critical topic: "Getting Drugs to Patients Faster - Investing in Discovery, Development & Clinical Trial Tech." 🚀 We explored how innovation in discovery, the latest advancements in clinical trial technology, and strategic investments are reshaping the future of healthcare, making life-saving treatments accessible to patients more efficiently than ever before. The exchange of ideas was invigorating, and the insights shared were both enlightening and inspiring. 🔍 Key Takeaway: The journey from discovery to patient access is complex, but with collaborative efforts and continued investment in technology and science, we can significantly accelerate timelines without compromising safety and efficacy. A huge thank you to my fellow panelists for sharing their expertise and to everyone who joined the session and engaged in this vital conversation. The future of healthcare innovation is bright, and I’m excited to be part of the journey! #InvestivalShowcase #HealthcareInnovation #DrugDevelopment #ClinicalTrials #Biotech #InvestingInInnovation

Hallo from Munich!! 👋 🇩🇪 The #REPO4EU consortium has arrived in the Bavarian city to celebrate the 4th #GeneralAssembly, hosted at Technische Universität München (Technical University of Munich)... there's a lot to catch up on before we officially kick off #RExPO24 tomorrow afternoon 🤩 If you're wondering what we've been up to, these are some of the crucial topics we've been discussing 👇 💊 Current status of the project, challenges and goals for next period (we're close to our 2nd anniversary already!) 💊 Crucial elements we need to implement for our #DrugRepurposing platform, with a big focus on #PatientNetworks and #RareDiseases 💊 A close first look at what our online platform will look like - lots of exciting developments happening in this area! 💊 Upcoming in-silico trials and potential new connections with further European #ClinicalData banks 💊 How to increase the impact of our research through ScienceOpen's Drug Repurposing Central (https://lnkd.in/ef4cCjaN) 💊 Location options for #RExPO25 next year!! Collaboration and knowledge exchange is at the heart of our project, and we're so fortunate to count on such a diverse pool of experts! As always, a big thank you to all the wonderful #REPO4EU partners for their continuous contributions and hard work towards shaping up the #FutureOfMedicine 🌟 Maastricht University, tp21 GmbH, Universität Wien, GeneSurge, STALICLA, Universität Hamburg, Technical University of Munich, Invicol GmbH, Sciomics, Universidad Politécnica de Madrid, DiHeSys - Digital Health Systems GmbH, H.M. Pharma Consultancy, Ipsis Pactis, AUSTRALO, Karolinska University Hospital, Brigham and Women's Hospital, Universitätsklinikum Bonn, Research Institute (RI), Arega Medical, Egnosis, 3D-PharmXchange, Radboudumc, Maastricht UMC+, ScienceOpen, BioLizard, Universidade do Porto, Machine2Learn, a Silo AI Company and University of Zurich.

Each Tuesday CCAM will highlight aspects of our #TechHubs designation. We will feature the steps that have gotten our APM Tech Hub to the point that we are at now, share what the designation means for our region, and the nation, and what’s next. To kick things off, let's talk about our 7 component projects that are being driven by our 44-member consortium. Each of these projects drives a specific aspect and developing assets of our #advancedpharma Tech Hub with a diverse and multi-disciplinary team of project leads and partners. Over the next few weeks, stay tuned to hear more about each of these projects as well as the consortium partners involved! 1. Governance: The Strategic Governance and Sustainability (CCAM) 2. Commercialization: The Acceleration of APM Product and Process Technologies into Commercialization (US Pharmacopeia) 3. Digital Tools: The Digital Readiness Transformation Project (Phlow) 4. Global Leadership: The Global Competitiveness Development (Greater Richmond Partnership) 5. Infrastructure: The Water and Wastewater Infrastructure Development (City of Petersburg, VA) 6. Infrastructure/Workforce Development - Training: The Pharmaceutical Training Facility (Civica Rx) 7. Workforce Development – Career Paths: End-to-End Workforce Development (J Sargeant Reynolds Community College) Activation Capital, Alliance for Building Better Medicine, America Achieves, AMPAC Fine Chemicals, Brightpoint Community College, BrightSpec, Inc., Center for Economic Inclusion, ChamberRVA, City of Richmond, Virginia, Richmond Public Schools, The Commonwealth Alliance for Rural Colleges, Community College Workforce Alliance, Crater Planning District Commission, CvilleBioHub, Richard Bland College of William & Mary, GENEDGE, GO Virginia, The Institute for Advanced Learning and Research, JMI, Julius, Network2WorkRVA, Petersburg City Public Schools, Richmond Region Tourism, University of Virginia, VABIOTECH, Medicines for All Institute, Virginia Economic Development Partnership, VIPC | Virginia Innovation Partnership Corporation, Virginia State University, Virginia's Gateway Region Economic Development Organization, Walmart #TechHubs #pharma #advancedmanufacturing #biotech #buildingbettermedicine